Brokerages expect Cardlytics Inc (NASDAQ:CDLX) to report earnings per share of ($0.15) for the current fiscal quarter, according to Zacks. Five analysts have provided estimates for Cardlytics’ earnings. The highest EPS estimate is ($0.10) and the lowest is ($0.24). Cardlytics also reported earnings of ($0.15) per share during the same quarter last year. The business is expected to report its next quarterly earnings results on Tuesday, November 12th.

According to Zacks, analysts expect that Cardlytics will report full-year earnings of ($0.62) per share for the current year, with EPS estimates ranging from ($0.80) to ($0.49). For the next fiscal year, analysts expect that the firm will report earnings of ($0.14) per share, with EPS estimates ranging from ($0.39) to $0.25. Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research firms that follow Cardlytics.

Cardlytics (NASDAQ:CDLX) last released its quarterly earnings results on Thursday, August 8th. The company reported ($0.12) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.35) by $0.23. The firm had revenue of $48.73 million for the quarter, compared to the consensus estimate of $43.77 million. Cardlytics had a negative return on equity of 66.01% and a negative net margin of 19.60%. The company’s revenue for the quarter was up 37.0% on a year-over-year basis. During the same period last year, the business posted ($0.21) EPS.

CDLX has been the topic of a number of research reports. KeyCorp raised their price target on Cardlytics from $25.00 to $26.00 and gave the stock an “overweight” rating in a research note on Friday, May 10th. Bank of America reiterated a “buy” rating and set a $32.00 target price (up from $22.00) on shares of Cardlytics in a research report on Wednesday, July 24th. JPMorgan Chase & Co. set a $43.00 target price on Cardlytics and gave the company a “buy” rating in a research report on Friday, August 9th. ValuEngine downgraded Cardlytics from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, April 23rd. Finally, William Blair started coverage on Cardlytics in a research report on Monday, July 1st. They set an “outperform” rating on the stock. One equities research analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $33.29.

Shares of CDLX stock traded up $0.72 on Monday, reaching $33.98. The stock had a trading volume of 245,100 shares, compared to its average volume of 349,568. The stock has a market cap of $765.78 million, a P/E ratio of -15.88 and a beta of 1.76. Cardlytics has a 1 year low of $9.80 and a 1 year high of $34.64. The company has a debt-to-equity ratio of 0.79, a quick ratio of 2.37 and a current ratio of 2.01. The company has a 50 day simple moving average of $29.08 and a 200 day simple moving average of $21.33.

In related news, Director Bryce Youngren sold 174,695 shares of Cardlytics stock in a transaction on Wednesday, August 14th. The stock was sold at an average price of $33.70, for a total transaction of $5,887,221.50. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Scott D. Grimes sold 4,000 shares of Cardlytics stock in a transaction on Tuesday, June 25th. The shares were sold at an average price of $23.76, for a total value of $95,040.00. The disclosure for this sale can be found here. Insiders have sold 814,894 shares of company stock worth $23,336,228 over the last quarter. 21.90% of the stock is owned by company insiders.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Gamco Investors INC. ET AL raised its holdings in Cardlytics by 2.6% during the second quarter. Gamco Investors INC. ET AL now owns 15,850 shares of the company’s stock valued at $412,000 after acquiring an additional 400 shares during the period. Bank of Montreal Can raised its holdings in Cardlytics by 16,371.4% during the second quarter. Bank of Montreal Can now owns 1,153 shares of the company’s stock valued at $30,000 after acquiring an additional 1,146 shares during the period. SG Americas Securities LLC raised its holdings in Cardlytics by 2.3% during the first quarter. SG Americas Securities LLC now owns 61,277 shares of the company’s stock valued at $1,014,000 after acquiring an additional 1,402 shares during the period. BlackRock Inc. raised its holdings in Cardlytics by 0.4% during the fourth quarter. BlackRock Inc. now owns 422,718 shares of the company’s stock valued at $4,578,000 after acquiring an additional 1,610 shares during the period. Finally, Oppenheimer Asset Management Inc. bought a new stake in Cardlytics during the second quarter valued at about $60,000. Institutional investors own 70.43% of the company’s stock.

Cardlytics Company Profile

Cardlytics, Inc operates a purchase intelligence platform in the United States and the United Kingdom. It operates in two segments, Cardlytics Direct and Other Platform Solutions. The company's platform is the Cardlytics Direct solution, a proprietary native bank advertising channel that enables marketers to reach consumers through their trusted and frequently visited online and mobile banking channels.

See Also: Does a trade war provide a risk to the global economy?

Get a free copy of the Zacks research report on Cardlytics (CDLX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Cardlytics (NASDAQ:CDLX)

Receive News & Ratings for Cardlytics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardlytics and related companies with MarketBeat.com's FREE daily email newsletter.